Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

nAMD

  • Home
  • nAMD
Predictive Value of Early Fluid Resolution for Long-term Durability of Faricimab in Neovascular Age-Related Macular Degeneration: A Synthesis of Evidence
Posted inClinical Updates news Ophthalmology

Predictive Value of Early Fluid Resolution for Long-term Durability of Faricimab in Neovascular Age-Related Macular Degeneration: A Synthesis of Evidence

Posted by MedXY By MedXY 03/24/2026
This review synthesizes clinical trial data demonstrating that rapid resolution of retinal fluid by week 12 with faricimab significantly predicts long-term treatment durability in patients with neovascular age-related macular degeneration.
Read More
Rapid Fluid Resolution with Faricimab Predicts Long-Term Treatment Durability in nAMD
Posted innews Ophthalmology

Rapid Fluid Resolution with Faricimab Predicts Long-Term Treatment Durability in nAMD

Posted by MedXY By MedXY 02/19/2026
A post hoc analysis of the TENAYA and LUCERNE trials demonstrates that early resolution of retinal fluid by week 12 with faricimab is a significant predictor of achieving extended every-16-week dosing intervals in patients with neovascular age-related macular degeneration.
Read More
  • Persistent Elevated Risk of Severe COVID-19 Outcomes in Pregnant and Postpartum Individuals Beyond the Pandemic Emergency
  • Unraveling Hepatitis B-Induced Liver Fibrosis: The Critical Role of Pyruvate, PPARα, and Reactive Oxygen Species
  • Unveiling the Role of IL-10-Neutralising Autoantibodies in Pediatric-Onset Inflammatory Bowel Disease: Prevalence, Persistence, and Clinical Implications
  • Decoding Microbial Shifts in Postoperative Crohn’s Disease: Insights into Recurrence Dynamics
  • Perfusion Imaging’s Role in Endovascular Therapy Outcomes for Posterior Cerebral Artery Stroke
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号
  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology health heart failure Hypertension immunotherapy inflammation MASLD mental health metformin Mortality myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prostate cancer public health quality of life randomized clinical trial randomized controlled trial randomized trial risk stratification SGLT2 inhibitors stroke targeted therapy type 1 diabetes type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in